pharmaceutical investing Zealand Pharma Doses First Patient in Phase 3 Trial with Dasiglucagon for Treatment of Congenital Hyperinsulinism
pharmaceutical investing Zealand Pharma achieves primary and key secondary endpoints in pivotal Phase 3 trial with dasiglucagon for severe hypoglycemia
Skyharbour Announces Additional Uranium Property Staking Increasing Total Portfolio to Over 682,000 Hectares in the Athabasca Basin, Saskatchewan
Graycliff Mobilizes Drill at Shakespeare Gold Project for Further Metallurgical Testing and to Expand Gold Zone
